Published in
Royal Society of Chemistry, RSC Chemical Biology, 4(3), p. 468-485, 2022
DOI: 10.1039/d1cb00244a
Links
Tools
Development of a NanoBRET assay to validate inhibitors of Sirt2-mediated lysine deacetylation and defatty-acylation that block prostate cancer cell migration
Journal article published in 2022 by
A. Vogelmann 
,
M. Schiedel ,
N. Wössner,
A. Merz,
D. Herp,
S. Hammelmann,
A. Colcerasa ,
G. Komaniecki,
J.-Y. Hong,
M. Sum,
E. Metzger,
E. Neuwirt ,
L. Zhang,
O. Einsle,
O. Groß
and other authors.
,
M. Schiedel ,
N. Wössner,
A. Merz,
D. Herp,
S. Hammelmann,
A. Colcerasa ,
G. Komaniecki,
J.-Y. Hong,
M. Sum,
E. Metzger,
E. Neuwirt ,
L. Zhang,
O. Einsle,
O. Groß
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Data provided by 
Abstract
Sirt2 inhibitors that show simultaneous inhibition of Sirt2 deacetylase and defatty-acylase activity block prostate cancer cell migration and their target engagement is shown by a newly developed NanoBRET assay.